Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Phase 1 Single Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add on Therapy in Patients With Cold Contact Urticaria, Symptomatic Dermographism and Cholinergic Urticaria

Next Previous
X
Search
Trial Profile

An Open Label, Phase 1 Single Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add on Therapy in Patients With Cold Contact Urticaria, Symptomatic Dermographism and Cholinergic Urticaria

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Barzolvolimab (Primary)
  • Indications Chronic urticaria; Urticaria
  • Focus Adverse reactions; Proof of concept
  • Sponsors Celldex Therapeutics

    • Most Recent Events

    • 10 Jun 2023 According to a Celldex Therapeutics Inc media release, data from this study were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2023.
    • 10 Jun 2023 Results presented in a Celldex Therapeutics Inc media release.
    • 08 Jun 2023 According to a Celldex Therapeutics media release, data from this study will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top